The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination Against Hepatitis A 9 to 11 Years After Its Implementation in the Tyva Republic, the Russian Federation

Overview

Journal Vaccines (Basel)

Date 2024 Aug 29

PMID 39204032

Authors

Maria A Lopatukhina

Karen K Kyuregyan

Anastasia A Karlsen

Fedor A Asadi Mobarkhan

Ilya A Potemkin

Vera S Kichatova

Olga V Isaeva

Lyudmila Yu Ilchenko

Anna A Saryglar

Mikhail I Mikhailov

Affiliations

Soon will be listed here.

Abstract

Since 2012, universal single-dose HAV vaccination in children aged 3 years and older has been implemented in the Tyva Republic, a region of the Russian Federation. The aim of this prospective non-interventional observational single-center study was to determine the immunological and epidemiological effectiveness of single-dose vaccination against hepatitis A 9 to 11 years after its implementation. The anti-HAV IgG antibodies were determined in two independent cohorts of children who were vaccinated with a single dose of monovalent pediatric inactivated vaccine (HAVRIX 720 EU) in Tyva in 2012 and recruited 9 years (Year 9 Cohort) and 11 years (Year 11 Cohort) after immunization. The seroprotection rates defined as anti-HAV antibody concentrations ≥10 mIU/mL reached 99.4% (95% CI: 98.2-99.9% [501/504]) in the Year 9 Cohort, but decreased significantly to 75.4% (95% CI: 73.0-77.6% [1006/1335]) in the Year 11 Cohort ( < 0.0001). The anti-HAV geometric mean concentrations decreased from 1446.3 mIU/mL (95% CI: 1347.1-1545.4 mIU/mL) in the Year 9 Cohort to 282.6 mIU/mL (95% CI: 203.8-360.8, < 0.0001) in the Year 11 Cohort. The HAV vaccination program resulted in zero rates of hepatitis A incidence in the Tyva Republic since 2016. However, the limited monitoring of HAV RNA in sewage and environmental samples demonstrated the ongoing circulation of both the regional epidemic strain of HAV genotype IA and another genotype IA strain imported recently from other parts of the Russian Federation, probably due to subclinical infections in non-vaccinated children under 3 years of age. Taken together, these data indicate the effectiveness of the single-dose HAV vaccination strategy but suggest the need to expand the vaccination program to include children aged 12 months and older to achieve maximum effectiveness.

References

Pinto R, DAndrea L, Perez-Rodriguez F, Costafreda M, Ribes E, Guix S . Hepatitis A virus evolution and the potential emergence of new variants escaping the presently available vaccines. Future Microbiol. 2012; 7(3):331-46. DOI: 10.2217/fmb.12.5. View

de Brito W, Souto F . Universal hepatitis A vaccination in Brazil: analysis of vaccination coverage and incidence five years after program implementation. Rev Bras Epidemiol. 2020; 23:e200073. DOI: 10.1590/1980-549720200073. View

Sabria A, Gregori J, Garcia-Cehic D, Guix S, Pumarola T, Manzanares-Laya S . Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients: Implications for immunization policies. EBioMedicine. 2018; 39:348-357. PMC: 6354442. DOI: 10.1016/j.ebiom.2018.11.023. View

Stuurman A, Marano C, Bunge E, De Moerlooze L, Shouval D . Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review. Hum Vaccin Immunother. 2016; 13(3):724-736. PMC: 5360128. DOI: 10.1080/21645515.2016.1242539. View

Yanez L, Lucero N, Barril P, Diaz M, Tenaglia M, Spinsanti L . Evidence of hepatitis A virus circulation in central Argentina: seroprevalence and environmental surveillance. J Clin Virol. 2013; 59(1):38-43. DOI: 10.1016/j.jcv.2013.11.005. View

Uruena A, Gonzalez J, Rearte A, Perez Carrega M, Calli R, Pagani M . Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina: High Prevalence of Protective Antibodies up to 9 Years After Vaccination. Pediatr Infect Dis J. 2016; 35(12):1339-1342. DOI: 10.1097/INF.0000000000001322. View

Fantilli A, Di Cola G, Castro G, Sicilia P, Cachi A, Marinzalda M . Hepatitis A virus monitoring in wastewater: A complementary tool to clinical surveillance. Water Res. 2023; 241:120102. DOI: 10.1016/j.watres.2023.120102. View

Sullivan G, Feinn R . Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ. 2013; 4(3):279-82. PMC: 3444174. DOI: 10.4300/JGME-D-12-00156.1. View

de Brito W, de Oliveira R, Silva J, Tubarao L, Ano Bom A, Melgaco J . Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine. J Viral Hepat. 2023; 30(7):615-620. DOI: 10.1111/jvh.13819. View

10.

Popova O, Kiuregian K, Ilchenko L, Isaeva O, Kozhanova T, Dmitriev P . [Epidemiological and molecular biological analysis of causes of rise of hepatitis A incidence in Republic of Tuva in 2008]. Zh Mikrobiol Epidemiol Immunobiol. 2010; (3):23-6. View

11.

Souto F, de Brito W, Fontes C . Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. Vaccine. 2019; 37(6):771-775. DOI: 10.1016/j.vaccine.2018.12.054. View

12.

Juliao P, Abadia I, Welby S, Wery S, Wong D, De Leon T . Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine. 2020; 39(1):26-34. DOI: 10.1016/j.vaccine.2020.11.030. View

13.

Mikhailov M, Lopatukhina M, Asadi Mobarhan F, Ilchenko L, Kozhanova T, Isaeva O . Universal Single-Dose Vaccination against Hepatitis A in Children in a Region of High Endemicity. Vaccines (Basel). 2021; 8(4). PMC: 7766627. DOI: 10.3390/vaccines8040780. View

14.

Perez-Sautu U, Costafreda M, Cayla J, Tortajada C, Lite J, Bosch A . Hepatitis a virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis. 2011; 17(4):734-7. PMC: 3377408. DOI: 10.3201/eid1704.101169. View

15.

Kyuregyan K, Lopatukhina M, Asadi Mobarkhan F, Kichatova V, Potemkin I, Isaeva O . Dynamic Changes in Hepatitis A Immunity in Regions with Different Vaccination Strategies and Different Vaccination Coverage. Vaccines (Basel). 2022; 10(9). PMC: 9506316. DOI: 10.3390/vaccines10091423. View

16.

Vizzotti C, Pippo T, Uruena A, Altuna J, Palopoli G, Hernandez M . Economic analysis of the single-dose immunization strategy against hepatitis A in Argentina. Vaccine. 2015; 33 Suppl 1:A227-32. DOI: 10.1016/j.vaccine.2014.12.077. View

17.

Espul C, Benedetti L, Cuello H, Houillon G, Rasuli A . Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat Med. 2013; 4:53-60. PMC: 3846818. DOI: 10.2147/HMER.S33847. View

18.

Mukomolov S, Kontio M, Zheleznova N, Jokinen S, Sinayskaya E, Stalevskaya A . Increased circulation of hepatitis A virus genotype IIIA over the last decade in St Petersburg, Russia. J Med Virol. 2012; 84(10):1528-34. DOI: 10.1002/jmv.23378. View

19.

Jeong S, Lee H . Hepatitis A: clinical manifestations and management. Intervirology. 2010; 53(1):15-9. DOI: 10.1159/000252779. View

20.

Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N . Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015; 33(42):5723-5727. DOI: 10.1016/j.vaccine.2015.07.008. View